Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2030

Conditions
Mature B-cell Non-Hodgkin Lymphoma
Interventions
DRUG

Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

DRUG

Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

DRUG

Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

DRUG

Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1

DRUG

Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4; Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,4(CNS2-3),8

DRUG

Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8

DRUG

Prednisone,Vincristine, Cyclophosphamide

Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1

Trial Locations (1)

201315

RECRUITING

Shanghai Children's Medical Center, Shanghai

All Listed Sponsors
collaborator

Shanghai Children's Medical Center

OTHER

collaborator

Nanjing Children's Hospital

OTHER

collaborator

Children's Hospital of Soochow University

OTHER

collaborator

West China Second University Hospital

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Wuhan TongJi Hospital

OTHER

lead

Children's Cancer Group, China

NETWORK

NCT07168980 - Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents | Biotech Hunter | Biotech Hunter